In fact, production of RANKL by tumor cells has been reported in breast (32), prostate (33) and oral cancers (34), and the RANKL produced by oral cancer cells has been reported to actually participate in cancer-associated bone destruction (34). This evidence concerns the gene TNFSF11 and cancer.